Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling

In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.

Astellas Set For India Build -Up, Sampada Gosavi says • Source: Astellas Pharma India

Astellas Pharma is changing gears in India, led by its gritty woman chief, who has moved up the ranks in the industry acing multiple roles along the way, including some in yesteryear’s traditional male bastions.

Breaking The Glass Ceiling

“The glass ceiling exists, but in your mind. You need to break it,” declared Sampada Gosavi, general manager and managing director, Astellas Pharma India, recounting her journey from her early days as a medical representative at an Indian firm to the helm of the major Japanese multinational.

Gosavi recalls being the lone women MR covering the Bombay Hospital in the initial years alongside many heavyweight male counterparts at a time when companies like Ranbaxy Laboratories Limited were an emerging force and the sales function was primarily the domain of men.

There was also a stint where Gosavi took on the role of sales head for Chattisgarh, previously part of the Indian state of Madhya Pradesh and Mumbai, and literally “worked out of a bag for 20-25 days in a month” alongside balancing time to raise her then three-year-old daughter.

“It's not been easy. I am not going to stand anywhere and say that it's been a bed of roses. It's been full of hard work,” Gosavi said, underscoring the value of a strong family support system.

The executive is also unabashed of leveraging female leadership traits such as empathy and other soft skills in a sector that’s predominantly led by male colleagues; in one prior leadership position, came the suggestion on the need to “behave like a man” but she would have none of it.

Gosavi underscored the need for women leaders to keep at it when the going gets tough – “build your network, a group of friends, with mentors who will pull you up,” she advises young aspiring leaders.

Gosavi herself has had a “great set of mentors” along her corporate journey and hopes that she can someday similarly be there for a young woman leader down the line.

Nevertheless, the “hard work” will always need to come from the mentee - you have to be on point, stand shoulder-to-shoulder with the guys, she emphasised.

Gosavi has previously served as associate director, sales and marketing for Abbott India

In a wide-ranging interview with Scrip, Astellas Pharma India general manager and managing director, Sampada Gosavi, discussed how the Japanese multinational expects to put the pedal to the metal in the country, the thrust on capability building, the Indian operating and regulatory environment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By 

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

 
• By 

Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy

More from Focus On Asia

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By 

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs